Semustine
- Generic Name
- Semustine
- Drug Type
- Small Molecule
- CAS Number
- 13909-09-6
- Unique Ingredient Identifier
- 6YY7T1T567
- Indication
1.常用于脑部原发肿瘤（如成胶质细胞瘤）及继发肿瘤；
2.治疗实体瘤，如与氟尿嘧啶合用治疗为爱及直肠癌；
3.治疗霍奇金病。
Outcomes of Patients After Allo-HSCT With Decitabine and NAC
Phase 3
Not yet recruiting
- Conditions
- Engraft FailureRelapseGVHD
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 100
- Registration Number
- NCT04945096
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
Phase 2
Recruiting
- Conditions
- LeukemiaGraft-versus-host-disease
- Interventions
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Yi Luo
- Target Recruit Count
- 46
- Registration Number
- NCT04688021
- Locations
- 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies
Phase 3
Recruiting
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 176
- Registration Number
- NCT04547049
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Soochow, China
🇨🇳Xinqiao Hospital, State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, China
🇨🇳The First Affiliated Hospital of Ningbo University, Ningbo, China
Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By Surgery
Phase 3
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- NSABP Foundation Inc
- Registration Number
- NCT00427570
Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 151
- Registration Number
- NCT00335075
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath